Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2014
At a glance
- Drugs Bevacizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 21 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Feb 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014, as per ClinicalTrials.gov record.
- 11 Jul 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.